Vitamin K2 ameliorates osteoarthritis by suppressing ferroptosis and extracellular matrix degradation through activation GPX4's dual functions

Biomed Pharmacother. 2024 Jun:175:116697. doi: 10.1016/j.biopha.2024.116697. Epub 2024 May 17.

Abstract

Vitamin K2 (VK2) is an effective compound for anti-ferroptosis and anti-osteoporosis, and Semen sojae praeparatum (Dandouchi in Chinese) is the main source of VK2. Chondrocyte ferroptosis and extracellular matrix (ECM) degradation playing a role in the pathogenesis of osteoarthritis (OA). Glutathione peroxidase 4 (GPX4) is the intersection of two mechanisms in regulating OA progression. But no studies have elucidated the therapeutic effects and mechanisms of VK2 on OA. This study utilized an in vivo rat OA model created via anterior cruciate ligament transection (ACLT) and an in vitro chondrocyte oxidative damage model induced by TBHP to investigate the protective effects and mechanisms of action of VK2 in OA. Knee joint pain in mice was evaluated using the Von Frey test. Micro-CT and Safranin O-Fast Green staining were employed to observe the extent of damage to the tibial cartilage and subchondral bone, while immunohistochemistry and PCR were used to examine GPX4 levels in joint cartilage. The effects of VK2 on rat chondrocyte viability were assessed using CCK-8 and flow cytometry assays, and chondrocyte morphology was observed with toluidine blue and alcian blue staining. The impact of VK2 on intracellular ferroptosis-related markers was observed using fluorescent staining and flow cytometry. Protein expression changes were detected by immunofluorescence and Western blot analysis. Furthermore, specific protein inhibitors were applied to confirm the dual-regulatory effects of VK2 on GPX4. VK2 can increase bone mass and cartilage thickness in the subchondral bone of the tibia, and reduce pain and the OARSI score induced by OA. Immunohistochemistry results indicate that VK2 exerts its anti-OA effects by regulating GPX4 to delay ECM degradation. VK2 can inhibit the activation of the MAPK/NFκB signaling pathway caused by reduced expression of intracellular GPX4, thereby decreasing ECM degradation. Additionally, VK2 can reverse the inhibitory effect of RSL3 on GPX4, increase intracellular GSH content and the GSH/GSSG ratio, reduce MDA content, and rescue chondrocyte ferroptosis. The protective mechanism of VK2 may involve its dual-target regulation of GPX4, reducing chondrocyte ferroptosis and inhibiting the MAPK/NFκB signaling pathway to decelerate the degradation of the chondrocyte extracellular matrix.

Keywords: Extracellular matrix degradation; Ferroptosis; GPX4’s dual functions; Knee osteoarthritis; MAPK/NFκB pathway; Vitamin K2.

MeSH terms

  • Animals
  • Cartilage, Articular / drug effects
  • Cartilage, Articular / metabolism
  • Cartilage, Articular / pathology
  • Cells, Cultured
  • Chondrocytes* / drug effects
  • Chondrocytes* / metabolism
  • Chondrocytes* / pathology
  • Disease Models, Animal
  • Extracellular Matrix* / drug effects
  • Extracellular Matrix* / metabolism
  • Ferroptosis* / drug effects
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Osteoarthritis* / drug therapy
  • Osteoarthritis* / metabolism
  • Osteoarthritis* / pathology
  • Phospholipid Hydroperoxide Glutathione Peroxidase* / metabolism
  • Rats
  • Rats, Sprague-Dawley*
  • Signal Transduction / drug effects
  • Vitamin K 2* / analogs & derivatives
  • Vitamin K 2* / pharmacology

Substances

  • Phospholipid Hydroperoxide Glutathione Peroxidase
  • Vitamin K 2
  • glutathione peroxidase 4, rat